drugset
drugset / Trial / NCT04855201

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

NCT04855201 ↗

Phase 1 Terminated 31 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to to evaluate the effect of ASP0367 on improvement of aerobic capacity relative to placebo, as well as evaluate the safety and tolerability of ASP0367 relative to placebo. This study will also evaluate the effect of ASP0367 on improvement of other aerobic capacity parameters relative to placebo, as well as evaluate the effect of ASP0367 on improvement of functional capacity relative to placebo.

Timeline

Start
2021-06-14
Primary completion
2022-12-16
Completion
2022-12-16

Outcome

Outcome not reported

Stopped: “Lack of Pharmacological effect”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bocidelpar Small molecule — Oral

Indications

No indication recorded.